Robert LeBoyer
Stock Analyst at Noble Capital Markets
(1.70)
# 2,982
Out of 4,695 analysts
16
Total ratings
22.22%
Success rate
7.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert LeBoyer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOVX GeoVax Labs | Maintains: Outperform | $6 → $10 | $2.44 | +309.84% | 2 | Aug 19, 2024 | |
| UNCY Unicycive Therapeutics | Initiates: Outperform | $6 | $0.80 | +650.47% | 1 | Feb 14, 2024 | |
| CVKD Cadrenal Therapeutics | Initiates: Outperform | $60 | $12.55 | +378.09% | 1 | Dec 18, 2023 | |
| ELDN Eledon Pharmaceuticals | Initiates: Outperform | $10 | $4.66 | +114.59% | 1 | Sep 27, 2023 | |
| MAIA MAIA Biotechnology | Initiates: Outperform | $14 | $2.07 | +576.33% | 1 | Feb 21, 2023 | |
| TNXP Tonix Pharmaceuticals Holding | Initiates: Outperform | $3,840 | $0.20 | +1,899,009.79% | 1 | Apr 18, 2022 | |
| LCTX Lineage Cell Therapeutics | Initiates: Outperform | $8 | $0.61 | +1,208.47% | 2 | Aug 19, 2021 | |
| PSTV Plus Therapeutics | Initiates: Buy | $120 | $1.35 | +8,788.89% | 1 | Jan 25, 2021 | |
| BNTC Benitec Biopharma | Downgrades: Neutral | n/a | $13.08 | - | 1 | Oct 5, 2020 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $12 | $8.18 | +46.70% | 1 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16,500 | $0.11 | +15,391,691.04% | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $16.55 | - | 1 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $4.15 | +261.45% | 2 | Mar 8, 2018 |
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $6 → $10
Current: $2.44
Upside: +309.84%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $6
Current: $0.80
Upside: +650.47%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $12.55
Upside: +378.09%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $4.66
Upside: +114.59%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $2.07
Upside: +576.33%
Tonix Pharmaceuticals Holding
Apr 18, 2022
Initiates: Outperform
Price Target: $3,840
Current: $0.20
Upside: +1,899,009.79%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $0.61
Upside: +1,208.47%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $120
Current: $1.35
Upside: +8,788.89%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $13.08
Upside: -
Anavex Life Sciences
Sep 28, 2020
Initiates: Buy
Price Target: $12
Current: $8.18
Upside: +46.70%
Aug 24, 2020
Initiates: Buy
Price Target: $16,500
Current: $0.11
Upside: +15,391,691.04%
Apr 10, 2018
Downgrades: Neutral
Price Target: n/a
Current: $16.55
Upside: -
Mar 8, 2018
Initiates: Buy
Price Target: $15
Current: $4.15
Upside: +261.45%